Latest News
and Innovations

Dec 13, 2024

NewAmsterdam Pharma Announces Closing of Upsized $479.0 Million Public Offering of Ordinary Shares and Pre-Funded Warrants, Including Full Exercise of the Underwriters’ Option to Purchase Additional Shares

Dec 12, 2024

NewAmsterdam Pharma Announces Pricing of Upsized $416.5 Million Public Offering of Ordinary Shares and Pre-Funded Warrants

Dec 10, 2024

NewAmsterdam Pharma Announces Commencement of $300 Million Public Offering of Ordinary Shares and Pre-Funded Warrants

Dec 10, 2024

NewAmsterdam Pharma Announces Positive Topline Data from Pivotal Phase 3 BROADWAY Clinical Trial Evaluating Obicetrapib in Patients with Atherosclerotic Cardiovascular Disease and/or Heterozygous Familial Hypercholesterolemia

Dec 6, 2024

NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

VIEW ALL NEWS
An anatomical heartAn anatomical heart

Driven by Patient Need,
Guided by Expertise

At NewAmsterdam Pharma, we are advancing a
new era of treatments for cardiovascular disease
(CVD) and other lipid-related conditions. By
prioritizing patients with unmet needs despite
currently available therapies, we are working
toward a reality where cardiovascular disease is no
longer the #1 killer of people worldwide.

LEARN MORE ABOUT US
A couple embracingA couple embracing

Developing a
Transformational Program

Guided by the latest clinical science and genetic research on CETP inhibition, our investigational asset, obicetrapib, was selected based on its potential ability to lower LDL-C and reduce cardiovascular risk.

DISCOVER OBICETRAPIB
Someone using a pipette to drop something in a petri dish